New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Evolocumab 2 endocrinologydiseasesdrugs
hyperglycemia 1 endocrinologydiseases
hyperlipidemia 1 endocrinologydiseases
obesity 3 endocrinologydiseases
rosiglitazone 2 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Evolocumab 27520 published, which focused on the effect of PCSK9 inhibitor to atherosclerosis. The results showed that in the Evolocumab (a kind of PCSK9 inhibitor) treatment group, the level of LDL-C was reduced by 59%, reaching an average
Evolocumab 27795 end point, a 20% reduction in the primary secondary endpoint, and no adverse events increased in the Evolocumab treatment group [[76]]. This study demonstrated that PCSK9 inhibitors could obviously reduce the risk
rosiglitazone 8247 statins and leptin, could obviously suppress mRNA expression of Angptl3 in mice, and both insulin and rosiglitazone could reduce ANGPTL3 secretion by a dose-dependent manner in immortalized human hepatocytes [[33]].
rosiglitazone 17942 and glucose metabolism was reciprocally. Data from Tikka et al. have revealed that both insulin and rosiglitazone could decrease the secretion of ANGPTL3 in a dose-dependent manner, and silencing of ANGPTL3 improved
Select Disease Character Offset Disease Term Instance
hyperglycemia 5514 KK mice and KK/Snk mice [[23]]. As is known to us, KK mice are a kind of animal models with obesity, hyperglycemia , hypercholesterolemia and hypertriglyceridaemia; conversely, KK/Snk mice, a sub-strain of the KK obese
hyperlipidemia 32538 carriers of ANGPTL3 LOF mutations, suggesting that ANGPTL3 LOF mutations can be served as a target for hyperlipidemia . Therefore, we can use the relevant technology to inactivate ANGPTL3 to treat dyslipidemia, obesity
obesity 5505 researching in KK mice and KK/Snk mice [[23]]. As is known to us, KK mice are a kind of animal models with obesity , hyperglycemia, hypercholesterolemia and hypertriglyceridaemia; conversely, KK/Snk mice, a sub-strain
obesity 30472 risk of CVD, drugs targeting ANGPTL3 may have considerable hope for reducing the risk of dyslipidemia, obesity and CVD.ConclusionsSince first discovered in 2002, ANGPTL3 has been considered as an important and novel
obesity 32645 hyperlipidemia. Therefore, we can use the relevant technology to inactivate ANGPTL3 to treat dyslipidemia, obesity and CVD. In conclusion, ANGPTL3 is an important hepatic derived regulator of plasma lipoprotein metabolism.

You must be authorized to submit a review.